Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 2026 ASCO Annual Meeting took place on May 29–June 2, 2026, in Chicago, IL, and online. This meeting attracts thousands of researchers and clinicians, who share the latest advances in the oncology field.

ASCO 2026

American Society of Clinical Oncology (ASCO) Annual Meeting
29 May–02 June 2026 | Chicago, IL & Online

ASCO 2026

American Society of Clinical Oncology (ASCO) Annual Meeting
29 May–02 June 2026 | Chicago, IL & Online
The 2026 ASCO Annual Meeting took place on May 29–June 2, 2026, in Chicago, IL, and online. This meeting attracts thousands of researchers and clinicians, who share the latest advances in the oncology field.
View all videos

Latest videos

View all
2:24
Improving the outcomes of patients with MCL who progress on BTK inhibitors
Manali Kamdar • 30 May 2026
2:07
DREAMM-9 final analysis: belamaf plus VRd for transplant-ineligible newly diagnosed multiple myeloma
Saad Usmani • 31 May 2026
1:35
Updated results from the inMMyCAR trial: in vivo CAR-T therapy KLN-1010 in R/R multiple myeloma
P. Joy Ho • 31 May 2026
1:33
The promise of GLP-1 receptor agonists for the prevention of acute leukemias in high-risk patients
Colton Jones • 31 May 2026

Multiple Myeloma

View all
3:09
How may baseline cfDNA fragmentomic signatures be used as a progression risk biomarker in MM?
Dory Abelman • 31 May 2026
2:55
CORAL next-generation AI model for guiding myeloma treatment decisions: insights and next steps
Arjun Rajanna • 31 May 2026

Lymphoma

View all
2:53
Practical advice for physicians managing the adverse events of loncastuximab tesirine in R/R DLBCL
Enrico Derenzini • 31 May 2026
1:47
Pooled analysis data from EPCORE NHL-2: epcoritamab plus platinum salvage in R/R DLBCL
Yasmin Karimi • 1 Jun 2026

Leukemia

View all
1:45
Safety and efficacy of azer-cel in patients with R/R NHL & CLL
Supriya Gupta • 29 May 2026
3:36
How do fewer chemotherapy plus venetoclax consolidation cycles impact toxicity and efficacy in AML?
Jennifer Marvin-Peek • 5 Jun 2026

MPNs

View all
1:58
MY-PAC: treatment patterns & outcomes in pacritinib-treated patients with MF & higher platelet count
Naveen Pemmaraju • 30 May 2026
2:21
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
Akriti Jain • 27 May 2026

Trial Updates

View all
2:00
Findings from a Phase Ib/II trial assessing azacitidine, venetoclax & ivosidenib in IDH1-mutated AML
Akriti Jain • 27 Jun 2026
1:47
Pooled analysis data from EPCORE NHL-2: epcoritamab plus platinum salvage in R/R DLBCL
Yasmin Karimi • 1 Jun 2026
4:50
DISC-0974, an anti-hemojuvelin mAb, for treating anemia in MF: results from the RALLY-MF trial
Aaron Gerds • 10 Jun 2026
2:24
Practice-changing advances in DLBCL immunotherapy in 2026
Joshua Brody • 29 May 2026
The content of VJHemOnc is intended for healthcare professionals